ArticleJournal of proteome research2026
Mass Spectrometric Detected Cancer Proteins as Resources for Cancer Research.
Article in Journal of proteome research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Protein evidence derived from mass spectrometry (MS) across cancer cohorts and model systems is extensive but remains fragmented across individual studies and repositories, limiting rapid retrieval and evidence-based benchmarking of cancer-context protein detection. Here we present the Mass Spectrometric Detected Cancer Proteins (MSCP) resource, an integrated database assembled from 27 large-scale cancer proteomics sources spanning human tumor cohorts, cancer cell lines, and patient-derived xenograft (PDX) models. Protein identifications were harmonized to UniProtKB-Swiss-Prot (release 2025_01) and integrated under FDR-controlled identification outputs to generate a unified catalog of 15,964 MS-supported human proteins. Benchmarking against neXtProt PE1 identified 525 proteins newly supported by MS evidence in the integrated cancer context, including proteins previously associated with chromosome-level evidence inconsistencies. Functional interpretation of the newly identified set using GO and Reactome enrichment highlighted immune- and barrier-associated processes and chromatin- and genome-regulatory pathways, including DNA methylation and histone deacetylation. Orthogonal verification using synthetic unique peptides confirmed representative newly identified proteins by concordant precursor
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.